LIR Life Sciences Pursues Needle-Free Obesity Therapy Delivery

LIR Life Sciences Corp. has filed a provisional patent application for a needle-free delivery platform targeting GLP/GIP-based therapies for obesity and metabolic diseases. This step aims to enhance delivery methods by using transdermal technologies, such as patches and creams, to replace injections. The application, submitted to the USPTO, details the combination of existing GLP/GIP drugs with proprietary carrier technology to effectively penetrate the skin and deliver therapeutic levels into the bloodstream.

The company's strategy focuses on a versatile platform compatible with current and future GLP- and GIP-based medications. Additionally, this filing supports their ongoing preclinical research, including a comparative study on a skin-applied GLP/GIP formulation in mice, which could shape final product development.

Ultimately, LIR aims to facilitate access to obesity treatments by reducing the need for injections, potentially improving patient adherence and expanding availability in various healthcare settings.